Skip to menu Skip to content Skip to footer

2014

Journal Article

Resveratrol does not benefit patients with non-alcoholic fatty liver disease

Chachay, Veronique S., Macdonald, Graeme A., Martin, Jennifer H., Whitehead, Jonathan P., O’Moore-Sullivan, Trisha M., Lee, Paul, Franklin, Michael, Klein, Kerenaftali, Taylor, Paul J., Ferguson, Maree, Coombes, Jeff S., Thomas, Gethin P., Cowin, Gary J., Kirkpatrick, Carl M. J., Prins, Johannes B. and Hickman, Ingrid J. (2014). Resveratrol does not benefit patients with non-alcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 12 (12), 2092-2103.e6. doi: 10.1016/j.cgh.2014.02.024

Resveratrol does not benefit patients with non-alcoholic fatty liver disease

2014

Conference Publication

Pre-operative cardiorespiratory fitness and post-operative cardiometabolic disease in liver transplant recipients

Wallen, M. P., Woodward, A., Skinner, T. L., Macdonald, G. A. and Coombes, J. S. (2014). Pre-operative cardiorespiratory fitness and post-operative cardiometabolic disease in liver transplant recipients. Australian Gastroenterology Week 2014, Broadbeach, QLD Australia, 22-24 October 2014. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12736_5

Pre-operative cardiorespiratory fitness and post-operative cardiometabolic disease in liver transplant recipients

2014

Conference Publication

Hepatic fibrosis is associated with small intestinal permeability in chronic liver disease due to hepatitis C, hepatitis B and non-alcoholic fatty liver disease, in subjects without ascites. A prospective cohort study using non-invasive techniques

Raj, Ashok, Holtmann, Gerald, Bhat, Purnima, Fletcher, Linda, Tran, Cuong, Vesey, David and Macdonald, Graeme (2014). Hepatic fibrosis is associated with small intestinal permeability in chronic liver disease due to hepatitis C, hepatitis B and non-alcoholic fatty liver disease, in subjects without ascites. A prospective cohort study using non-invasive techniques. Asian Pacific Digestive Week, Bali, Indonesia, 22‐25, 2014. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia . doi: 10.1111/jgh.12766_2

Hepatic fibrosis is associated with small intestinal permeability in chronic liver disease due to hepatitis C, hepatitis B and non-alcoholic fatty liver disease, in subjects without ascites. A prospective cohort study using non-invasive techniques

2014

Journal Article

Total body fat and the risk of Barrett's oesophagus - A bioelectrical impedance study

Kendall, Bradley J., Macdonald, Graeme A., Prins, Johannes B., O'Brien, Suzanne and Whiteman, David C. (2014). Total body fat and the risk of Barrett's oesophagus - A bioelectrical impedance study. Cancer Epidemiology, 38 (3), 266-272. doi: 10.1016/j.canep.2014.03.006

Total body fat and the risk of Barrett's oesophagus - A bioelectrical impedance study

2014

Conference Publication

Fat oxidation over a range of exercise intensities: fitness versus fatness

Croci, Ilaria, Hickman, Ingrid J., Wood, Rachel E., Borrani, Fabio, Macdonald, Graeme A. and Byrne, Nuala M. (2014). Fat oxidation over a range of exercise intensities: fitness versus fatness. 6th Exercise and Sport Science Australia Conference, Adelaide, SA, Australia, 10-12 April 2014.

Fat oxidation over a range of exercise intensities: fitness versus fatness

2013

Journal Article

Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease

Croci, Ilaria, Byrne, Nuala M., Choquette, Stephane, Hills, Andrew P., Chachay, Veronique S., Clouston, Andrew D., O'Moore-Sullivan, Trisha M., Macdonald, Graeme A., Prins, Johannes B. and Hickman, Ingrid J. (2013). Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut, 62 (11), 1625-1633. doi: 10.1136/gutjnl-2012-302789

Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease

2013

Journal Article

A Pilot Randomised Study of the Metabolic and Histological Effects of Exercise in Non-alcoholic Steatohepatitis

Hickman, Ingrid J., Byrne, Nuala M., Croci, Ilaria, Chachay, Veronique S., Clouston, Andrew D., Hills, Andrew P., Bugianesi, Elisabetta, Whitehead, Jonathan P, Gastaldelli, Amalia, O'Moore-Sullivan, Trisha M., Prins, Johannes B. and Macdonald, Graeme A . (2013). A Pilot Randomised Study of the Metabolic and Histological Effects of Exercise in Non-alcoholic Steatohepatitis. Journal of Diabetes and Metabolism, 4 (8) 8. doi: 10.4172/2155-6156.1000300

A Pilot Randomised Study of the Metabolic and Histological Effects of Exercise in Non-alcoholic Steatohepatitis

2013

Journal Article

The risk of Barrett's esophagus associated with abdominal obesity in males and females

Kendall, Bradley J., Macdonald, Graeme A., Hayward, Nicholas K., Prins, Johannes B., O'Brien, Suzanne, Whiteman, David C., Study of Digestive Health, Green. Adele C., Parsons, Peter G., Pavey, Sandra J., Purdie, David M. and Webb, Penelope M. (2013). The risk of Barrett's esophagus associated with abdominal obesity in males and females. International Journal of Cancer, 132 (9), 2192-2199. doi: 10.1002/ijc.27887

The risk of Barrett's esophagus associated with abdominal obesity in males and females

2013

Conference Publication

Obstructive Sleep Apnea, Gastroesophageal Reflux and Barrett's Esophagus in a Population-Based Case-Control Study

Lindam, Anna P., Kendall, Bradley J., Thrift, Aaron P., Macdonald, Graeme A., Lagergren, Jesper and Whiteman, David C. (2013). Obstructive Sleep Apnea, Gastroesophageal Reflux and Barrett's Esophagus in a Population-Based Case-Control Study. Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Orlando Fl, May 18-21, 2013. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.

Obstructive Sleep Apnea, Gastroesophageal Reflux and Barrett's Esophagus in a Population-Based Case-Control Study

2013

Conference Publication

Advanced Hepatic Fibrosis Is Associated With Increased Small Intestinal Permeability: A Novel Evaluation Incorporating a Plasma-Based Assay and Transient Elastography

Raj, Ashok, Macdonald, Graeme A., Bhat, Purnima, Tran, Cuong D. and Holtmann, Gerald (2013). Advanced Hepatic Fibrosis Is Associated With Increased Small Intestinal Permeability: A Novel Evaluation Incorporating a Plasma-Based Assay and Transient Elastography. Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Orlando Florida, 18 - 21 May, 2013. Philadelphia, United States of America: Elsevier Inc..

Advanced Hepatic Fibrosis Is Associated With Increased Small Intestinal Permeability: A Novel Evaluation Incorporating a Plasma-Based Assay and Transient Elastography

2013

Journal Article

Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C

Horsfall, Leigh, Macdonald, Graeme, Scott, Ian, Skoien, Richard, Khatun, Mohsina, Moss, Cathy, Seligman, Clare, Kardash, Christine, Poxon, Vicki and Powell, Elizabeth E. (2013). Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C. Australian Health Review, 37 (2), 218-222. doi: 10.1071/AH12162

Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C

2013

Conference Publication

Management and outcomes of side effects with focus on anaemia in patients with hepatitis c genotype 1 infection: The telaprevir early access program in patients from Australia and New Zealand

Strasser, S. I., Roberts, S. K., Gane, E. J., Macdonald, G. A., Thompson, A. J., Weltman, M. D., Weilert, F., Hill, A., Laeuffer, J. and Dore, G. J. (2013). Management and outcomes of side effects with focus on anaemia in patients with hepatitis c genotype 1 infection: The telaprevir early access program in patients from Australia and New Zealand. The Australian Gastroenterology Week 2013, Melbourne, VIC Australia, 7 - 9 October 2013. Richmond, VIC 3121 Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12365_14

Management and outcomes of side effects with focus on anaemia in patients with hepatitis c genotype 1 infection: The telaprevir early access program in patients from Australia and New Zealand

2013

Book Chapter

Physical activity and cardiovascular fitness in patients with NAFLD: Clinical importance and therapeutic implications

Hickman, Ingrid J., Macdonald, Graeme A. and Byrne, Nuala M. (2013). Physical activity and cardiovascular fitness in patients with NAFLD: Clinical importance and therapeutic implications. Non-alcoholic fatty liver disease : A practical guide. (pp. 132-148) Chichester, W Sussex, U,K.: Wiley-Blackwell. doi: 10.1002/9781118556153.ch12

Physical activity and cardiovascular fitness in patients with NAFLD: Clinical importance and therapeutic implications

2013

Conference Publication

Significant hepatic fibrosis is associated with increased small intestinal permeability

Raj, A. S., Macdonald, G. A., Bhat, P., Fletcher, L. M., Tran, C., Black, M. and Holtmann, G. (2013). Significant hepatic fibrosis is associated with increased small intestinal permeability. The Australian Gastroenterology Week 2013, Melbourne, VIC Australia, 7 - 9 October 2013. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12365_5

Significant hepatic fibrosis is associated with increased small intestinal permeability

2013

Conference Publication

Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: a randomised, double blind, placebo-controlled trial

Chachay, V. S., Martin, J. H., Prins, J. B., Whitehead, J. P., O'Moore-Sullivan, T. M., Lee, P., Franklin, M., Klein, K., Taylor, P. J., Ferguson, M., Coombes, J. S., Thomas, G. P., Cowin, G. J., Kirkpatrick, C. M. J., Macdonald, G. A. and Hickman, I. J. (2013). Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: a randomised, double blind, placebo-controlled trial. Australian Gastroenterology Week 2013, Melbourne, VIC, Australia, 7-9 October 2013. Richmond, VIC, Australia: Wiley-Blackwell. doi: 10.1111/jgh.12365_5

Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: a randomised, double blind, placebo-controlled trial

2013

Conference Publication

Trends in treatment of recurrent hepatitis C after liver transplantation

Forgan-Smith, K. R., Stuart, K. A., Tallis, C., Macdonald, G. A. and Fawcett, J. (2013). Trends in treatment of recurrent hepatitis C after liver transplantation. The Australian Gastroenterology Week 2013, Melbourne, VIC Australia, 7 - 9 October 2013. Richmond, VIC 3121 Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12365_14

Trends in treatment of recurrent hepatitis C after liver transplantation

2013

Conference Publication

Abdominal obesity and Barrett's oesophagus - does hip obesity reduce the risk?

Kendall, B. J., Macdonald, G. A., Prins, J. B., O'Brien, S. and Whiteman, D. C. (2013). Abdominal obesity and Barrett's oesophagus - does hip obesity reduce the risk?. Australian Gastroenterology Week 2013, Melbourne Australia, 7-9 October 2013. Richmond Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12365_7

Abdominal obesity and Barrett's oesophagus - does hip obesity reduce the risk?

2013

Conference Publication

Treatment of hepatitis c genotype 1 patients with severe fibrosis or compensated cirrhosis: The telaprevir early access program in patients from Australia and New Zealand

Macdonald, G. A., Roberts, S. K., Dore, G. J., Gane, E. J., Thompson, A. J., Weltman, M. D., Weilert, F., Hill, A., Laeuffer, J. and Strasser, S. I. (2013). Treatment of hepatitis c genotype 1 patients with severe fibrosis or compensated cirrhosis: The telaprevir early access program in patients from Australia and New Zealand. The Australian Gastroenterology Week 2013, Melbourne, VIC Australia, 7 - 9 October 2013. Richmond, VIC 3121 Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12365_14

Treatment of hepatitis c genotype 1 patients with severe fibrosis or compensated cirrhosis: The telaprevir early access program in patients from Australia and New Zealand

2012

Journal Article

The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis

Tan, Terrence C. H., Crawford, Darrell H. G., Franklin, Michael E., Jaskowski, Lesley A., Macdonald, Graeme A., Jonsson, Julie R., Watson, Melanie J., Taylor, Paul J. and Fletcher, Linda M. (2012). The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. Liver International, 32 (9), 1391-1399. doi: 10.1111/j.1478-3231.2012.02828.x

The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis

2012

Journal Article

Hepatitis C treatment outcomes in Australian clinics

Gidding, Heather F., Law, Matthew G., Amin, Janaki, Ostapowicz, George, Weltman, Martin, Macdonald, Graeme A., Sasadeusz, Joe J., Haber, Paul A. W., George, Jacob and Dore, Gregory J. (2012). Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 196 (10), 633-637. doi: 10.5694/mja12.10014

Hepatitis C treatment outcomes in Australian clinics